These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19034219)

  • 1. ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial.
    Kim MJ; Tsinalis D; Franz S; Binet I; Gürke L; Mihatsch MJ; Steiger J; Thiel G; Dickenmann M
    Ann Transplant; 2008; 13(4):21-7. PubMed ID: 19034219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of daclizumab, an interleukin 2 receptor antibody, to anti-thymocyte globulin-Fresenius induction therapy in kidney transplantation.
    Abou-Jaoude MM; Ghantous I; Almawi WY
    Mol Immunol; 2003 Jul; 39(17-18):1083-8. PubMed ID: 12835081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM; Yang SL; Wu WZ; Tan JM
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction therapy after cardiac transplantation: a comparison of anti-thymocyte globulin and daclizumab in the prevention of acute rejection.
    Carlsen J; Johansen M; Boesgaard S; Andersen CB; Arendrup H; Aldershvilet J; Mortensen SA
    J Heart Lung Transplant; 2005 Mar; 24(3):296-302. PubMed ID: 15737756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients.
    Grego K; Arnol M; Bren AF; Kmetec A; Tomaziĉ J; Kandus A
    Transplant Proc; 2007 Dec; 39(10):3093-7. PubMed ID: 18089329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis.
    Hao WJ; Zong HT; Cui YS; Zhang Y
    Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G; Saraji A; Salem S; Mehrsai A; Nikoobakht MR; Taherimahmoudi M; Rezaeidanesh M; Asadpour A
    Transplant Proc; 2009 Sep; 41(7):2794-6. PubMed ID: 19765437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-shot antithymocyte globuline and daclizumab induction in simultaneous pancreas and kidney transplant recipient: three-year results.
    Schulz T; Flecken M; Kapischke M; Busing M
    Transplant Proc; 2005 May; 37(4):1818-20. PubMed ID: 15919476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B; Light S; Hardie IR; Lin A; Johnson JR
    Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretransplantation GAD-autoantibody status to guide prophylactic antibody induction therapy in simultaneous pancreas and kidney transplantation.
    Ringers J; van der Torren CR; van de Linde P; van der Boog PJ; Mallat MJ; Bonifacio E; Roep BO; de Fijter JW
    Transplantation; 2013 Oct; 96(8):745-52. PubMed ID: 23912172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anti interleukin-2 receptor alpha antibodies (daclizumab) application for the treatment of kidney recipients].
    Izvolskaja N; Rainiene T; Dainys B
    Medicina (Kaunas); 2003; 39 Suppl 1():166-70. PubMed ID: 12761441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The outcome of induction therapy with monoclonal antibodies in kidney transplantation among Iranian patients: a prospective study.
    Naderi GH; Mehraban D; Ganji MR; Jafarpouriani M; Latif AH
    Transplant Proc; 2009 Sep; 41(7):2768-71. PubMed ID: 19765430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.
    Abou-Jaoude MM; Ghantous I; Najm R; Afif C; Almawi WY
    Transplant Proc; 2003 Nov; 35(7):2731-2. PubMed ID: 14612096
    [No Abstract]   [Full Text] [Related]  

  • 14. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab.
    Burton CM; Andersen CB; Jensen AS; Iversen M; Milman N; Boesgaard S; Arendrup H; Eliasen K; Carlsen J
    J Heart Lung Transplant; 2006 Jun; 25(6):638-47. PubMed ID: 16730569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients.
    Morris JA; Hanson JE; Steffen BJ; Chu AH; Chi-Burris KS; Gotz VP; Gordon RD
    Clin Transplant; 2005 Jun; 19(3):340-5. PubMed ID: 15877795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved long-term survival after intra-operative single high-dose ATG-Fresenius induction in renal transplantation: a single centre experience.
    Kaden J; May G; Völp A; Wesslau C
    Ann Transplant; 2009; 14(3):7-17. PubMed ID: 19644154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of high dose ATG bolus administration on rewascularization in kidney graft patients--long term results.
    Samsel R; Pliszczyński J; Chmura A; Korczak G; Włodarczyk Z; Cieciura T; Lagiewska B; Glyda M; Wyzgal J; Paczek L; Durlik M; Rowiński W
    Ann Transplant; 2008; 13(1):32-9. PubMed ID: 18344941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-shot antithymocyte globulin (ATG) induction for pancreas/kidney transplantation: ATG-Fresenius versus Thymoglobulin.
    Schulz T; Papapostolou G; Schenker P; Kapischke M
    Transplant Proc; 2005 Mar; 37(2):1301-4. PubMed ID: 15848703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients.
    Noël C; Abramowicz D; Durand D; Mourad G; Lang P; Kessler M; Charpentier B; Touchard G; Berthoux F; Merville P; Ouali N; Squifflet JP; Bayle F; Wissing KM; Hazzan M
    J Am Soc Nephrol; 2009 Jun; 20(6):1385-92. PubMed ID: 19470677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.